title: Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
authors.forename: Silvia
authors.initials: S
authors.lastname: Mangiacavalli
authors.forename: Lara
authors.initials: L
authors.lastname: Pochintesta
authors.forename: Federica
authors.initials: F
authors.lastname: Cocito
authors.forename: Alessandra
authors.initials: A
authors.lastname: Pompa
authors.forename: Paolo
authors.initials: P
authors.lastname: Bernasconi
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.forename: Alessandro
authors.initials: A
authors.lastname: Corso
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D002882:Chromosomes, Human, Pair 13 / Q000648:ultrastructure; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D016158:Genes, p53; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D000077269:Lenalidomide; D007952:Leukemia, Plasma Cell / Q000235:genetics*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000235:genetics*; D011241:Prednisone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D017384:Sequence Deletion; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome; D014314:Trisomy
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D008558:Melphalan; D011241:Prednisone
keywords: TP53 (p53); clonal evolution; multiple myeloma